2.50Open2.50Pre Close0 Volume0 Open Interest10.00Strike Price0.00Turnover815.62%IV-12.11%PremiumJul 26, 2024Expiry Date3.31Intrinsic Value100Multiplier1DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.7223Delta0.1037Gamma1.78Leverage Ratio-0.4122Theta-0.0003Rho-1.29Eff Leverage0.0013Vega
Altimmune Stock Discussion
Altimmune Announces Publication of Clinical Study of Pemvidutide in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Journal of Hepatology
Altimmune (Nasdaq: ALT) has published data from a 12-week clinical trial of pemvidutide, a GLP-1/glucagon dual receptor agonist, in the Journal of Hepatology. The study focused on metabolic dysfunction-associated steatotic liver disease (MASLD). Key findings include:
- Up to 68.5% relative reduction in liver fat con...
Larger Image: tradingview.com...
$Altimmune(ALT.US)$
No comment yet